The book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine.

Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book.

Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions.

Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book.

The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.

Provides a unique attempt to make a bridge between human microbiome and real protocols for medical practice Offers a new vision on human microbiome data as an instrument of personal health and disease balance Summarizing probiotics efficacy data within the prism of 3P medicine approach

Autorentext
Nadiya Boyko, Professor, DSc. Microbiology is Head of the Department of Clinical Laboratory Diagnostics and Pharmacology, Director of Research Development and Educational Centre of Molecular Microbiology and Mucosal Immunology Uzhhorod National University, Ukraine. The research field priorities particularly are personalised nutrition and individual pharmabiotics in regulation of human [gut] microbiota for prevention of noncommunicable diseases, precise diagnostics, P4 medicine. Job-related skills: 35 years' experience in research and leading research in bioeconomy, food and health relevant fields, mainly dealing with food safety, human nutrition and human microbiome, individual nutrition needs, FCDB, impact of food on human host, mucosal immune response etc. She is a lecturer for native and foreign (English) speaking students, supervising PhD students, regularly acting as invited lecturer for the variety of international and national meetings, and master classes. She is an intensive participant with oral presentations, discussions, debates, etc. in health and food relevant EU and other countries leader associations' workshops, congresses, committees, ambassador for Global Harmonization Initiative , president for SOMED (2022-2024). She is dealing with a lot of national and international groups of contacts on regular bases and participating as p.i. in around 40 projects. She is also the author of about 350 scientific works, including 100 papers in professional scientific journals, more than 50 publications in the peer-reviewed journals, and Chapter in Elsevier press, index H=12. She is specialist with expertise in life sciences, participated in international projects like BaSeFood, JSO-ERA EU FP7, CAPINFOOD (SEE), BacFoodNet (COST), ODiN (FP7), FoodWARD (Erasmus) and H2020 (SKIN) projects.

Prof. Dr. Golubnitschaja is the head of the world first Predictive, Preventive Personalised (3P) Medicine unit at the Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany. She is educated in journalism, biotechnology and medicine and has been awarded research fellowships in Austria, Russia, UK, Germany, Netherlands, and Switzerland (early and predictive diagnostics in paediatrics, neurosciences and cancers).

Dr. Golubnitschaja is the author of more than 400 international publications (research and review articles, position papers, books, book and congress contributions) in the innovative field of predictive, preventive and personalised medicine (3PM) with the main research focuses on sub-optimal health conditions, pre- and perinatal diagnostics, diagnostics of cardiovascular disease and neurodegenerative pathologies, predictive diagnostics in cancer and diabetes. In 1990-2002 she published as Olga Labudova. Cumulative Google Scholar h -index is 60 .

Awards: National & International Fellowship of theAlexander von Humboldt-Foundation; Highest Prize in Medicine and Eiselsberg-Prize in Austria; Springer-Nature Award; EMA Award.

In years 2009 2021 Dr. Golubnitschaja was the Secretary-General and since September 2021 she is the President of the European Association for Predictive, Preventive & Personalised Medicine (EPMA, Brussels) networking over 50 countries worldwide. She is Editor-in-Chief of the EPMA J. (actual Clarivate IF 6.543, Scopus CiteScore 11.3) and Editor-in-Chief of the Book Series Advances in Predictive, Preventive & Personalised Medicine, Springer Nature.

Dr. Golubnitschaja is the European Representative in the EDR-Network at the National Institutes of Health USA. She acts as a regular reviewer in over 50 clinical and scientific journals and as a grant reviewer of inter/national funding bodies in European and other countries. Dr. Golubnitschaja is an evaluation expert at the European Commission. In years 2010-2013 she was involved in creating the PPPM related contents of the European Programme Horizon 2020. Currently, She is Vice-Chair of the Habilitation Committee (responsible for all medical specialisations) at the Medical Faculty, University of Bonn, Germany and is Vice-Chair of the Evaluation Panel for Marie Curie Mobility Actions at the European Commission in Brussels.

Inhalt
Chapter 1: Microbiome in the framework of Predictive, Preventive and Personalised Medicine.- Chapter 2: Artificial Intelligence-based Predictive, Preventive, and Personalised Medicine applied to Bacteraemia Diagnosis.- Chapter 3: Vaginal microbiome and its role in HPV induced cervical carcinogenesis.- Chapter 4: Microbiome in lean Individuals: Phenotype-specific Risks and Outcomes.- Chapter 5: Microbiome and Obesity.- Chapter 6: Pathophysiology-based approach for individualized use of probiotics and prebiotics for metabolic syndrome: implementing predictive, preventive, and personalized medical approach.- Chapter 7: Selection of prebiotic substances for individual prescription.- Chapter 8: Probiotic Administration for the Prevention and Treatment of Gastrointestinal, Metabolic and Neurological Disorders.- Chapter 9: Microbial therapy with indigenous bacteria. From idea to clinical evidence.- Chapter 10: Fecal microbiota transplantation in diseases not associated with Clostridium difficile: current status and future therapeutic option.- Chapter 11: Personalized microbiome correction by application of individual nutrition for type 2 diabetes treatment.- Chapter 12: Pro-, pre- and synbiotic supplementation and oxalate homeostasis in 3PM context: focus on microbiota oxalate-degrading activity.- Chapter 13: In vitro study of specific properties of probiotic strains for effective and personalized probiotic therapy.- Chapter 14: Probiotic concepts of predictive, preventive, and personalized medical approach for obesity: Lactic acid bacteria and Bifidobacteria probiotic strains improve glycemic and inflammation profiles.- Chapter 15: Oral Microbiome and Innate Immunity in Health and Disease: Building a Predictive, Preventive and Personalized Therapeutic approach.